ClonoSIGHT™: MRD Detection and Quantification
The first clinical product developed using the LymphoSIGHT platform is the ClonoSIGHT process, which empowers physicians with ultra-sensitive minimal residual disease (MRD) detection and quantification for patients with lymphoid cancers.
MM Multiple Myeloma
DLBCL Diffuse Large B-Cell Lymphoma
CLL Chronic Lymphocytic Leukemia
ALL Acute Lymphoblastic Leukemia
MCL Mantle Cell Lymphoma
Clinical validation of additional indications is ongoing